HAVRIX INJ
Manufacturer Details
GLAXO SMITH KLINE
Compositions:
Hepatiis A virus HM 175 strain virus strain 360(paediatrics) or 720 (junior) or 1440 (adult ) ELISA units per dose absorbed onto aluminium hydroxide injection,
Strength
|
Rate
|
Packing Style
|
Pediatric
|
747.00
|
injection
|
Junior
|
1139.00
|
injection
|
Adult
|
1980.00
|
injection
|
List of Related Indications:
- Immunisation again Hepatitis A
List Of Drugs:
- Hepatitis A Vaccine @- (Feb 1998)
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Preliminary results suggest that concomittant admin. of a wide variety of other vaccines is unlikely to interfere with the immune response to hepatitis A vaccine When comcomittant admin. of other vaccines or IG is required, they should be given with different syringes and at different injection sites
Indication:
Active imunization against infections caused by HAV in persons over 1 year age
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Hepatitis -A Vaccine 05-02-1998
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Hepatitis A Vaccine GlaxoSmithKline 24-02-2010
Vaccine
Adverse Reaction:
Adverse events to hepatitis are usualy mild & confirmed to the first few days after vaccination wit spontaneous recovery.
Local- pain at the site of action, redness, swelling hematoma, irritations/edema, pruritis.
These usually subside within 72 hrs and no specific treatment is needed. Relevent trreatment may be given whenever needed.
Systemic- Fever . 37.5c axillary,asthenia/drowsiness.headache, myalgia, arthalgia, gastrointestinal disorders, behavoiural changes, skin disorders
Contra-Indications:
Contraindications-
Hyperacidity to the vaccine or any component of formulation Acute infection diseases or other serious ilness Acute febrile illness with temperatures above 37.5C Immunodificiency status A history of anaphlaxis or any other serious allergic reaction to vaccines A monor a febrile illness or mild upper respiratory tract infection is not usually a reason to defer immnization with the vaccine
Dosages/ Overdosage Etc:
Indication-
Active imunization against infections caused by HAV in persons over 1 year age
Dosage-
Add 1.0 ml sterile water fot injection & shake well the powder completely dissolves. Then inject a single dose of 1ml subsequently over the deltoid muscle of upaer arm. No boster dose ie required
Other Information:
For Availability/supplies
Contact -
1.Indian Drug Manufacturers Association (IDMA)
Phone- 022- 24944624/ 24974308
Fax- 022- 24950723
Email- idma@vsnl.com
Website: www.idma-assn.org
2.Bulk Drug Manufacturers Association (India)(BDMA)
Phone - 040-23703910/ 23706718
Fax- 040-23704804
Email- info@bdmai.org
Website: www.info@bdmai.org
Patient Information:
Fully inform patients or guardians of th benefits and risks of imunization Hepatitis A vaccine is indicated for a variety of situations.
For persons travelling to endemic or epidemic areas, consult the local advisory regarding specific locales Travellers should take al necessary precautions to avoid contact with or ingestion of contaminated food or water The duration of immunity following a complete schedule of immunization with Hepatitis a vaccine has not been established
Pharmacology/ Pharmacokinetics:
Pharmcokinetics-
Hepatitis A confers immunity against HIV infection by the induction of specific antibodies against the virus. The vaccine confers immunity against HAV virus by including antibodies titres than those obtained after passive immunization with immunoglobulins.